Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea

Study Identifier
P18-839
CT.gov Identifier
NCT03925441
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Dermatology - Psoriasis (PsO)
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    4 - 17 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Children and adolescents who are diagnosed with pediatric chronic severe plaque psoriasis. * Prior to participating in the study, adalimumab treatment was determined according to clinical judgement of the physician. * Participants (or legal representative) who voluntarily agreed to participate in this study and signed informed consent.
    Exclusion Criteria:
    * Participants with contraindication to adalimumab as listed in the approved Korean label. * Participants with prior treatment with adalimumab.

    Protocol Summary

    The objective of this study is to evaluate the real world safety and effectiveness of adalimumab (Humira) for the treatment of Korean patients with pediatric chronic severe plaque psoriasis under a routine treatment practice.

    Study Locations

    Location
    Status
    Location
    Ajou University Hospital /ID# 207843
    Suwon, Gyeonggido, Republic of Korea, 16499
    Status
    Not applicable